Search research articles
Contact Us
Filters
Showing results (181-190 of 234) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors
Neeltje Steeghs, Ferry A L M Eskens, Hans Gelderblom, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2006
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Michael Leahy, Isabelle Ray-Coquard, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2012
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors
Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, et al.
Journal of the National Cancer Institute
|
November 4, 2004
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes
Ron H J Mathijssen, Floris A de Jong, Ron H N van Schaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2009
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial
Axel Le Cesne, Martine Van Glabbeke, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2009
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors
Ferry A L M Eskens, Neeltje Steeghs, Jaap Verweij, et al.
The Oncologist
|
February 23, 2013
Evaluation of patient enrollment in oncology phase I clinical trials
Diane A J van der Biessen, Merlijn A Cranendonk, Gaia Schiavon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2002
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors
Maja J A de Jonge, Cornelis J A Punt, Alex Sparreboom, et al.
The Oncologist
|
October 9, 2010
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia
Jessica M van der Bol, Floris A de Jong, Ron H van Schaik, et al.
Cancer Chemotherapy and Pharmacology
|
August 4, 2010
Effects of methimazole on the elimination of irinotecan
Jessica M van der Bol, Theo J Visser, Walter J Loos, et al.
Page
of 24
Search research articles
Search
Showing results (181-190 of 234) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors
Neeltje Steeghs, Ferry A L M Eskens, Hans Gelderblom, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2006
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Michael Leahy, Isabelle Ray-Coquard, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2012
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors
Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, et al.
Journal of the National Cancer Institute
|
November 4, 2004
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes
Ron H J Mathijssen, Floris A de Jong, Ron H N van Schaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2009
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial
Axel Le Cesne, Martine Van Glabbeke, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2009
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors
Ferry A L M Eskens, Neeltje Steeghs, Jaap Verweij, et al.
The Oncologist
|
February 23, 2013
Evaluation of patient enrollment in oncology phase I clinical trials
Diane A J van der Biessen, Merlijn A Cranendonk, Gaia Schiavon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2002
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors
Maja J A de Jonge, Cornelis J A Punt, Alex Sparreboom, et al.
The Oncologist
|
October 9, 2010
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia
Jessica M van der Bol, Floris A de Jong, Ron H van Schaik, et al.
Cancer Chemotherapy and Pharmacology
|
August 4, 2010
Effects of methimazole on the elimination of irinotecan
Jessica M van der Bol, Theo J Visser, Walter J Loos, et al.
Page
of 24